261 related articles for article (PubMed ID: 27812149)
1. Renal Outcomes of Pioglitazone Compared with Acarbose in Diabetic Patients: A Randomized Controlled Study.
Chen YH; Tarng DC; Chen HS
PLoS One; 2016; 11(11):e0165750. PubMed ID: 27812149
[TBL] [Abstract][Full Text] [Related]
2. Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin.
Derosa G; Mereu R; D'Angelo A; Salvadeo SA; Ferrari I; Fogari E; Gravina A; Palumbo I; Maffioli P; Randazzo S; Cicero AF
J Clin Pharm Ther; 2010 Oct; 35(5):565-79. PubMed ID: 20831680
[TBL] [Abstract][Full Text] [Related]
3. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH
Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
[TBL] [Abstract][Full Text] [Related]
4. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes.
Hanefeld M; Brunetti P; Schernthaner GH; Matthews DR; Charbonnel BH;
Diabetes Care; 2004 Jan; 27(1):141-7. PubMed ID: 14693980
[TBL] [Abstract][Full Text] [Related]
5. Comparative study of sitagliptin with pioglitazone in Japanese type 2 diabetic patients: the COMPASS randomized controlled trial.
Takihata M; Nakamura A; Tajima K; Inazumi T; Komatsu Y; Tamura H; Yamazaki S; Kondo Y; Yamada M; Kimura M; Terauchi Y
Diabetes Obes Metab; 2013 May; 15(5):455-62. PubMed ID: 23279373
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of adding pioglitazone or sitagliptin to patients with type 2 diabetes insufficiently controlled with metformin and a sulfonylurea.
Liu SC; Chien KL; Wang CH; Chen WC; Leung CH
Endocr Pract; 2013; 19(6):980-8. PubMed ID: 23807528
[TBL] [Abstract][Full Text] [Related]
7. Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial.
Aljabri K; Kozak SE; Thompson DM
Am J Med; 2004 Feb; 116(4):230-5. PubMed ID: 14969650
[TBL] [Abstract][Full Text] [Related]
8. Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus.
Meneghini LF; Traylor L; Schwartz SL
Endocr Pract; 2010; 16(4):588-99. PubMed ID: 20350924
[TBL] [Abstract][Full Text] [Related]
9. Retrospective comparison of voglibose or acarbose as an add-on therapy to sulfonylureas in Western Indian patients with uncontrolled overweight/obese type 2 diabetes.
Talaviya PA; Saboo BD; Dodiya HG; Rao SK; Joshi SR; Modh VB; Ghadiya SV
Diabetes Metab Syndr; 2016; 10(2):88-91. PubMed ID: 26777258
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial.
Schernthaner G; Matthews DR; Charbonnel B; Hanefeld M; Brunetti P;
J Clin Endocrinol Metab; 2004 Dec; 89(12):6068-76. PubMed ID: 15579760
[TBL] [Abstract][Full Text] [Related]
11. Can a selective PPARγ modulator improve glycemic control in patients with type 2 diabetes with fewer side effects compared with pioglitazone?
DePaoli AM; Higgins LS; Henry RR; Mantzoros C; Dunn FL;
Diabetes Care; 2014 Jul; 37(7):1918-23. PubMed ID: 24722496
[TBL] [Abstract][Full Text] [Related]
12. Effect of Acarbose on Glycemic Variability in Patients with Poorly Controlled Type 2 Diabetes Mellitus Receiving Stable Background Therapy: A Placebo-Controlled Trial.
Derosa G; Franzetti I; Querci F; D'Angelo A; Maffioli P
Pharmacotherapy; 2015 Nov; 35(11):983-90. PubMed ID: 26598090
[TBL] [Abstract][Full Text] [Related]
13. Podocyte as a potential target of inflammation: role of pioglitazone hydrochloride in patients with type 2 diabetes.
Xing Y; Ye S; Hu Y; Chen Y
Endocr Pract; 2012; 18(4):493-8. PubMed ID: 22441004
[TBL] [Abstract][Full Text] [Related]
14. Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and rosiglitazone or insulin and acarbose in type 2 diabetes.
Yilmaz H; Gursoy A; Sahin M; Guvener Demirag N
Acta Diabetol; 2007 Dec; 44(4):187-92. PubMed ID: 17726570
[TBL] [Abstract][Full Text] [Related]
15. Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study.
Abdul-Ghani M; Migahid O; Megahed A; Adams J; Triplitt C; DeFronzo RA; Zirie M; Jayyousi A
Diabetes Care; 2017 Mar; 40(3):325-331. PubMed ID: 28096223
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: a double blind, randomized comparison with pioglitazone.
Pareek A; Chandurkar N; Thomas N; Viswanathan V; Deshpande A; Gupta OP; Shah A; Kakrani A; Bhandari S; Thulasidharan NK; Saboo B; Devaramani S; Vijaykumar NB; Sharma S; Agrawal N; Mahesh M; Kothari K
Curr Med Res Opin; 2014 Jul; 30(7):1257-66. PubMed ID: 24669876
[TBL] [Abstract][Full Text] [Related]
17. Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials.
Monami M; Vitale V; Ambrosio ML; Bartoli N; Toffanello G; Ragghianti B; Monami F; Marchionni N; Mannucci E
Adv Ther; 2012 Sep; 29(9):736-46. PubMed ID: 22923161
[TBL] [Abstract][Full Text] [Related]
18. [Six-month effectiveness and tolerability of pioglitazone in combination with sulfonylureas or metformin for the treatment of type 2 diabetes mellitus].
Rodríguez A; Reviriego J; Polavieja P; Mesa J
Med Clin (Barc); 2008 Nov; 131(19):721-30. PubMed ID: 19091199
[TBL] [Abstract][Full Text] [Related]
19. Acarbose in NIDDM patients with poor control on conventional oral agents. A 24-week placebo-controlled study.
Lam KS; Tiu SC; Tsang MW; Ip TP; Tam SC
Diabetes Care; 1998 Jul; 21(7):1154-8. PubMed ID: 9653611
[TBL] [Abstract][Full Text] [Related]
20. Metformin or Acarbose Treatment Significantly Reduced Albuminuria in Patients with Newly Diagnosed Type 2 Diabetes Mellitus and Low-Grade Albuminuria.
Pan Q; Xu Y; Yang N; Gao X; Liu J; Yang W; Wang G
Med Sci Monit; 2018 Dec; 24():8941-8949. PubMed ID: 30531690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]